Objective: To determine the expression of lipoxygenase (LOX) pathway receptors in ovarian cancer as a potential target for anti-LOX—based therapy. Study design: Paraffin-embedded tumor samples from epithelial ovarian cancer patients were used to construct tissue microarrays to stain for the proposed sites of inhibition of a LOX inhibitor (5-LOX, LTB4-BLT1, and LTB4-BLT2). Results: 245 samples were available for interpretation. Strong expression was demonstrated in 45%, 34%, and 6% of ovarian cancer for LTB4-BLT2, LTB4-BLT1, and 5-LOX, respectively. Expression of LTB4-BLT2 correlated with advanced stage III/IV disease (P = .05), suboptimal debulking (P = .07), and platinum resistance (P = .03). No correlation was seen with regard to disease-free survival. Conclusions: LOX pathway receptor expression was found in the majority of cancers evaluated. Additionally, LTB4-BLT2 expression portends worse clinical parameters for ovarian cancer. Thus, further investigation on the role of LOX pathway in ovarian cancer is warranted.
Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
2.
Alberts DS, Green S., Hannigan EV, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer . J Clin Oncol. 1992;10:706-717.
3.
McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1-6.
4.
Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21: 3194-3200.
5.
Ding XZ,Talamonti MS, Bell RH Jr ,Adrian TEA novel anti-pancreatic cancer agent, LY293111 . Anticancer Drugs. 2005;16: 467-473.
6.
Ara G., Teicher BACyclooxygenase and lipoxygenase inhibitors in cancer therapy. Prostaglandins Leukot Essent Fatty Acids. 1996;54:3-16.
7.
Teicher BA, Korbut TT, Menon K., Holden SA, Ara G.Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies . Cancer Chemother Pharmacol. 1994;33:515-522.
8.
Barnes MN, Chhieng DF, Dreher M., et al. Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: initial examination of celecoxib as a chemopreventive agent. Gynecol Oncol. 2005 ;98:376-382.
9.
Rodriguez-Burford C., Barnes MN, Oelschlager DK, et al. Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res. 2002;8: 202-209.
10.
Tang DG, Chen YQ, Honn KVArachidonate lipoxygenases as essential regulators of cell survival and apoptosis . Proc Natl Acad Sci U S A. 1996;93:5241-5246.
Bortuzzo C. , Hanif R., Kashfi K., Staiano-Coico L., Shiff SJ, Rigas B.The effect of leukotrienes B and selected HETEs on the proliferation of colon cancer cells. Biochim Biophys Acta. 1996;1300:240-246.
13.
Hennig R., Ding XZ, Tong WG, et al. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol. 2002;161:421-428.
14.
Haraldsdottir S., Guolaugsdottir E., Ingolfsdottir K., Ogmundsdottir HMAnti-proliferative effects of lichen-derived lipoxygenase inhibitors on twelve human cancer cell lines of different tissue origin in vitro. Planta Med. 2004;70: 1098-1100.
15.
Ding XZ, Iversen P., Cluck MW, Knezetic JA, Adrian JELipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells . Biochem Biophys Res Commun. 1999;261: 218-223.
16.
Ghosh J., Myers CEInhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci U S A. 1998;95:13182-13187.
17.
Baetz T., Eisenhauer E., Siu L., et al. A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours. Invest New Drugs. 2007;25:217-225.
18.
Hennig R.,Ventura J., Segersvard R., et al. LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice. Neoplasia. 2005;7:417-425.
19.
Tong WG, Ding XZ, Adrian TEThe mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer cells. Biochem Biophys Res Commun. 2002;296:942-948.
20.
Munkarah AR , Genhai Z., Morris R., et al. Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells . Gynecol Oncol. 2003;88:429-433.
21.
Harris RE, Beebe-Donk J., Doss H., Burr Doss D.Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep. 2005;13:559-583.
22.
Ding XZ, Adrian TERole of lipoxygenase pathways in the regulation of pancreatic cancer cell proliferation and survival. Inflammopharmacology. 2001;1-8.
23.
Budman DR, Calabro A.Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY293111. Anticancer Drugs. 2004;15:877-881.
24.
Hennig R., Ding XZ, Tong WG, Witt RC, Jovanovic BD, Adrian TEEffect of LY293111 in combination with gemcitabine in colonic cancer. Cancer Lett. 2004;210:41-46.
25.
Schwartz GK, Weitzman A., O'Reilly E., et al. Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors. J Clin Oncol. 2005;23:5365-5373.
26.
Zhang W., McQueen T., Schober W., Rassidakis G., Andreeff M., Konopleva M.Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation. Leukemia. 2005;19:1977-1984.
27.
Tsao MS, Sakurada A., Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133-144.
